SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

PALYNZIQ

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the U.S. (since 2018 for adults, expanded to adolescents 12+ in February 2026) and in the EU (since 2019 for ages 16+, with a May 2026 CHMP positive opinion for further expansion).
Why 4/10
PALYNZIQ is already approved and commercially marketed (FDA approved May 2018 for adults, expanded to adolescents 12+ in February 2026). There is no pending PDUFA date or pivotal readout for this drug in the next ~12 months, so the next binary catalyst is absent. The drug is a meaningful but not dominant part of BioMarin's portfolio (trails VOXZOGO in revenue).
Actionable Insight NEUTRAL

PALYNZIQ has no upcoming binary catalyst; the next major BioMarin catalysts are VOXZOGO PDUFA dates (Feb 28, 2027 for full achondroplasia approval, May 30, 2027 for hypochondroplasia). Watch Q4 2026 earnings for PALYNZIQ's post-adolescent-expansion revenue trajectory and any EMA adolescent label decision for Europe.

Price Chart

Loading chart...

Executive Summary

PALYNZIQ (pegvaliase-pqpz) is BioMarin Pharmaceutical's enzyme substitution therapy for phenylketonuria (PKU), a rare genetic disorder. First approved by the FDA in May 2018 for adults, it received a key label expansion in February 2026 to include adolescents aged 12 and older, based on positive Phase 3 PEGASUS trial data. The drug carries a black-box warning for anaphylaxis and requires daily injections, which limits adoption versus oral alternatives. PALYNZIQ generated $135 million in Q2 2026 revenue (up 27% YoY) and is part of BioMarin's growing Metabolic Conditions portfolio, but it is not the company's largest product (VOXZOGO at $245M in Q3 2026 is bigger). With no pending regulatory catalyst for PALYNZIQ in the next 12 months, the stock's near-term binary events center on VOXZOGO PDUFA dates in early 2027.

How It Works

PALYNZIQ is an enzyme substitution therapy for phenylketonuria (PKU), a genetic disease where the body cannot break down the amino acid phenylalanine (Phe) from food. The drug replaces the missing or defective enzyme (PAH) with a lab-made enzyme (pegvaliase) that breaks down Phe in the blood, preventing toxic buildup that can cause brain damage. It is given as a daily injection under the skin.

Trial Status

PALYNZIQ is FDA-approved and commercially marketed. The pivotal Phase 3 PEGASUS trial supported the February 2026 adolescent label expansion, demonstrating statistically significant blood phenylalanine lowering versus diet alone in patients aged 12-17. Real-world evidence studies are ongoing for long-term safety monitoring.

The Two-Sided Case

▲ Bull Case5
PALYNZIQ is the only FDA-approved enzyme substitution therapy for PKU, with no direct competitors in its class, giving it a unique position in a growing market.
The February 2026 FDA approval for adolescents aged 12+ expanded the addressable patient population significantly, and the company expects full-year 2026 PALYNZIQ revenue to increase year-over-year.
PALYNZIQ delivered $135M in Q2 2026 revenue, up 27% year-over-year, and patient numbers grew across all BioMarin metabolic therapies.
The global PKU treatment market is estimated at $1.1B in 2026 and projected to grow to $2.0B by 2033 (8.1% CAGR), providing a long growth runway.
Analyst consensus is bullish on BMRN with 27 of 35 analysts rating Buy/Strong Buy, a mean price target of $91.56 (57.4% implied upside from $58.16), and major holders like BlackRock ($1.17B), Dodge & Cox ($849M), and Primecap ($812M) maintain large positions.
▼ Bear Case5
PALYNZIQ carries an FDA black-box warning for anaphylaxis, which may occur at any time during treatment, limiting patient uptake and requiring supervised administration.
The drug is an injectable enzyme therapy requiring daily injections, which creates a compliance hurdle versus oral alternatives like Kuvan (sapropterin) and pipeline oral candidates such as sepiapterin and JNT-517.
BioMarin's Q3 2026 GAAP net loss widened to -$123M, and full-year 2026 Non-GAAP EPS guidance was slashed ~40% to $2.80-$3.10 due to acquisition-related charges, raising concerns about overall profitability.
PKU gene therapy candidates in the pipeline could eventually displace enzyme replacement therapies like PALYNZIQ if successful.
Elevated short-sale volume (z-score 1.63 vs BMRN's own history) and several large institutional exits (Citadel near-exit, Point72 exit, Wellington exit) in Q2 2026 signal bearish sentiment around the stock.

Upcoming Catalysts

  • Potential EMA decision on expanding PALYNZIQ label to adolescents aged 12+ in Europe (no firm date announced)
  • Q4 2026 earnings report (expected February 2027) showing PALYNZIQ revenue trajectory post-adolescent expansion
  • Ongoing real-world safety data readouts for adolescent patients

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 17

Hover a chip for the title
1 drugs.com2 biomarin.com3 biomarin.com4 hcp.biomarin.com5 accessdata.fda.gov6 prnewswire.com7 news.alphastreet.com8 hcp.biomarin.com9 grandviewresearch.com10 persistencemarketresearch.com11 en.wikipedia.org12 ema.europa.eu13 ema.europa.eu14 pdufa.bio15 sec.gov16 marketbeat.com17 benzinga.com